Concord Healthcare Group Co., Ltd ( Concord Medical) was established in July 2008 and is affiliated to Concord Holdings, listed on the New York Stock Exchange.
Concord Holdings (NYSE: CCM) is a holding company listed on the New York Stock Exchange in 2009 with the joint recommendation of JP Morgan, Morgan Stanley and CICC and with medical services as its main business. Founded in 1997, CCM is a medical service provider specializing in cancer prevention, diagnosis and treatment, education and research. Its main business includes financial leasing, import and export of second- and third-class medical devices, and investment in upstream and downstream enterprises in the healthcare industry, etc.
As a national high-tech enterprise, Concord Medical has established its foothold in the core cities of Beijing, Shanghai and Guangzhou, and has deployed the construction and operation of international medical institutions for cancer across China. At present, the company has formed the combination of offline and online medical businesses featuring precision radiotherapy provided through medical institutions and Internet medical services. With the help of medical and Internet technologies, Concord Medical has empowered such closely combined areas as the third-party medical partners’ cloud system solutions, independent imaging centers + Artificial Intelligence (AI), and the incubation, transformation, application and output, etc. of the science and technology innovation centers for medical technology.
The company's main business includes medical institutions and Internet hospitals that can provide a full range of diagnosis and treatment services throughout the entire tumor process, as well as a network that empowers a wide range of third-party customers by relying on integrated tumor-related services, covering medical solutions, management and technical support, equipment rental and support services.
Concord Medical has in-depth cooperation with world-renowned medical institutions like MD Anderson Cancer Center and Mayo Clinic in various key medical areas, such as medical technology, operation technology, clinical experience, scientific research, and talent training, to jointly promote the standardization and internationalization of tumor diagnosis and treatment in China.
The company has participated in the formulation of a number of industry standards by the National Cancer Center of China, and in 2021, the company was approved as a pilot project for 5G medical and health applications by the Ministry of Industry and Information Technology and the National Health Commission of China. The company's subsidiary Healthingkon Technology is also a state-level high-tech enterprise in China, and has been selected into the list of the first batch of "specialized and special new" small and medium-sized enterprises of Beijing in 2022.
In 2018, 2020, and 2021 respectively, the company obtained strategic investments from well-known investment institutions like CICC Capital, CITIC Industrial Investment, and Shengshan Assets, which transformed it into a mixed-ownership medical technology development group. Concord Medical will work with our partners to jointly promote new changes in China's medical services in the future.